# Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/IPSC/century-therapeutics-to-participate-in-piper-sandler-37th-annual-healthcare-conf-4361fd95
Ticker: IPSC
Company: Century Therapeutics
Source: Century Therapeutics
Published: 2025-11-25 21:01 EST
## Summary

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced...

## Article Body
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, NY, as follows:

Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will participate in the “State of the Art in Cell Therapy” panel discussion at 12:00 p.m. ET on Tuesday, December 2, 2025.

Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, and Dr. Cowan will participate in a webcasted fireside chat at 10:00 a.m. ET on Wednesday, December 3, 2025.

A live webcast of the fireside chat will be available on the Investors page of Century’s website at www.centurytx.com . An archived replay of the webcast will be available for at least 30 days.

About Century Therapeutics Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

For More Information:

Century Therapeutics Douglas Carr Senior Vice President, Finance investor.relations@centurytx.com

JPA Health Sarah McCabe smccabe@jpa.com
## Recent Company News
- 2026-07-09 12:00 EST — [Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-dat-b81a8a73) — Source: Century Therapeutics
- 2026-06-08 20:05 EST — [New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026](https://biopharmsignal.com/news/IPSC/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-e65eb4fc) — Source: Century Therapeutics
- 2026-05-13 12:00 EST — [Century Therapeutics Reports First Quarter Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-first-quarter-financial-results-and-business-update-c4d76676) — Source: Century Therapeutics
- 2026-04-30 20:05 EST — [Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentation-of-cnty-813-preclinical-data-0932a2d5) — Source: Century Therapeutics
- 2026-03-12 12:00 EST — [Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-full-year-2025-financial-results-and-business-updat-7b62a847) — Source: Century Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)